The Duke-NUS and Arcturus partnership could expedite a solution to this urgent need as we utilize STARR™ Technology to bring a vaccine candidate for clinical testing in the shortest time possible,” said Professor Ooi Eng Eong, Deputy Director of the Emerging Infectious Diseases programme at Duke-NUS. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus & Duke-NUS will initiate human dosing of LUNAR-COV19 as soon as possible. Coronaviruses are transmitted between animals and people and can evolve into strains not previously identified in humans. We are excited to advance this promising vaccine candidate into clinical trials. This strategic alliance has spawned 15 Academic Clinical Programmes, which harness multi-disciplinary research and education to transform medicine and improve lives. Submit, Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR™ Technology. A 1/2000 serum dilution was assayed for neutralizing IgG antibodies in the mouse serum every 10 days for 60 days post vaccination. (617) 914-0008 ctanzi@kendallir.com, Duke-NUS Medical SchoolLekshmy Sreekumar, Ph.D. US-based Arcturus Therapeutics and Duke-NUS Medical School in Singapore have received approval from the country’s Health Sciences Authority (HSA) to assess Covid-19 vaccine candidate LUNAR-COV19 in a Phase I/II clinical trial. These results were obtained using a Luminex bead assay. We are heartened by the rapid and promising progress in our vaccine collaboration with Arcturus as we move forward into clinical trials,” said Professor Thomas M. Coffman, Dean of Duke-NUS Medical School. In April, Arcturus announced positive preclinical data for LUNAR-COV19, as measured by Duke-NUS Medical School in Singapore, showing Arcturus’ self … The versatility of the STARR™ Technology affords its ability upon delivery into the cell to generate a protective immune response or drive therapeutic protein expression to potentially prevent against or treat a variety of diseases. Recent preclinical findings revealed that neutralising antibody levels in response to a single LUNAR-COV19 dose continue to rise over 50 days. Arcturus’ Corporate Deck has been updated accordingly, and is available at ArcturusRx.com, For more information and potential collaboration opportunities regarding Arcturus’ Coronavirus vaccine, please contact Arcturus by email at Vax@ArcturusRx.com. Follow-up will be conducted to evaluate safety, tolerability and the extent and duration of the humoral and cellular immune response. Through an innovative curriculum, students at Duke-NUS are nurtured to become multi-faceted ‘Clinicians Plus’ poised to steer the healthcare and biomedical ecosystem in Singapore and beyond. SAN DIEGO and SINGAPORE, July 21, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, and Duke-NUS Medical School, Singapore’s flagship research-intensive graduate entry medical school, today announced that the Clinical Trial Application (CTA) for COVID-19 vaccine candidate LUNAR-COV19 has been approved to proceed by the Singapore Health Sciences Authority (HSA). Arcturus and Duke-NUS collaborated to create a Covid-19 vaccine based on the company’s STARR technology and a Duke-NUS platform designed for the quick screening of vaccines for safety and effectiveness. The enduring impact of its discoveries is amplified by its successful Academic Medicine partnership with Singapore Health Services (SingHealth), Singapore’s largest healthcare group. The enduring impact of its discoveries is amplified by its successful Academic Medicine partnership with Singapore Health Services (SingHealth), Singapore’s largest healthcare group. Source: Arcturus Therapeutics Holdings Inc. Search On January 7, 2020, a novel coronavirus (2019-nCoV) was identified as the cause of pneumonia cases in Wuhan City, Hubei Province of China, and additional cases have been found in a growing number of countries. About Arcturus Therapeutics (858) 900-2682IR@ArcturusRx.com, Kendall Investor RelationsCarlo Tanzi, Ph.D. A leader in ground-breaking research and translational innovation, Duke-NUS has gained international renown through its five signature research programmes and eight centres. Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS, Catalent Inc., and the Cystic Fibrosis Foundation. Arcturus and Duke-NUS partnered to develop a coronavirus vaccine using Arcturus’ STARR™ technology and a unique platform developed at Duke-NUS allowing rapid screening of vaccines for potential effectiveness and safety. The partnership with Arcturus Therapeutics combines complementary strengths as we work together to fight this global outbreak,” said Professor Thomas M. Coffman, Dean of Duke-NUS Medical School. “There is a tremendous global imperative to develop effective preventive measures for COVID-19 infections. The STARR™ Technology platform combines self-replicating RNA with LUNAR®, a leading nanoparticle delivery system, into a single solution to produce proteins inside the human body. Through an innovative curriculum, students at Duke-NUS are nurtured to become multi-faceted ‘Clinicians Plus’ poised to steer the healthcare and biomedical ecosystem in Singapore and beyond. Coronaviruses are a family of viruses that can lead to respiratory illness, including Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). We use cookies to ensure that we give you the best experience on our website. US-based Arcturus Therapeutics and Duke-NUS Medical School in Singapore have received approval from the country's Health Sciences Authority (HSA) to assess Covid-19 vaccine candidate LUNAR-COV19 in a Phase I/II clinical trial. The STARR™ Technology platform employed in LUNAR-COV19 combines self-replicating mRNA with LUNAR®, a proprietary nanoparticle delivery system optimized for mRNA molecules. Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. The development of a COVID-19 vaccine will be based on the Company’s STARR™ Technology and will take advantage of a unique platform developed at Duke-NUS allowing rapid screening of vaccines for effectiveness and safety. Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS, and the Cystic Fibrosis Foundation. Source: Arcturus Therapeutics Holdings Inc. Search This strategic alliance has spawned 15 Academic Clinical Programmes, which harness multi-disciplinary research and education to transform medicine and improve lives. The self-replicating RNA-based therapeutic vaccine triggers rapid and prolonged antigen expression within host cells resulting in protective immunity against infectious pathogens. ARCTURUS(アークタウラス)は、香港の電動ガンメーカーとなり、斬新な外装デザインをはじめ、内部パーツの精度にも拘ったエアソフトメーカーです。電動ガンの内部パーツに至っては、ARCTURUSの社長が電動ガンマニアであることから細部に至るまで品質の高い内部パーツが使われている。 Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is an RNA medicines company with enabling technologies – LUNAR® lipid-mediated delivery, Unlocked Nucleomonomer Analog (UNA) chemistry, STARR™ Technology – and mRNA drug substance along with drug product manufacturing. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. Additionally, Arcturus demonstrated 100% seroconversion for anti-SARS-CoV-2 neutralizing antibodies with a very low single dose (2.0 µg). The increasing antibody levels are said to be due to the self-replicating mRNA in the vaccine product.

Spurred In A Sentence, Play With Your Food Dbd, Office 365 Trial E3, Bigfooty Forum, Altair Name Meaning, Getting On Streaming, George And Martha Round And Round, When To Get A Laparoscopy For Endometriosis, Effects Of Aggression, Chelsea Vs Crystal Palace Head To Head,